hero-team

Our team.

Saurabh Saha, M.D., Ph.D., is Chief Executive Officer and a member of the Board of Directors of Centessa Pharmaceuticals. Most recently, as Senior Vice President of Research & Development at Bristol Myers Squibb, Saurabh led translational medicine across all therapeutic areas spanning discovery, early development through late development, and commercialization. In 2019, he led the Research & Development diligence in the acquisition of Celgene by BMS and subsequently managed key aspects of the integration across both organizations. During his tenure, Saurabh laid the foundation for the BMS Research & Development headquarters in Cambridge, MA, serving as site head and establishing a research focus on discovering new cancer treatments for immunotherapy resistance.

Previously, Saurabh was a Venture Partner at Atlas Venture where he held leadership positions with a number of its portfolio biotech companies, including Chief Medical Officer of Synlogic, and Chief Executive Officer of Delinia until its sale to Celgene in early 2017. In 2008, he established the translational research and development organization at BioMed Valley Discoveries where he served as Chief Scientific Officer and later President and was responsible for leading the development and demonstrating human effectiveness of two first-in-class cancer therapies. Earlier in his career, Saurabh was a Management Consultant in the pharmaceutical practice at McKinsey & Company and subsequently appointed Director and Head of the New Indications Discovery Unit at Novartis. He is on the editorial boards of a number of medical journals and is an Associate member and Global Clinical scholar at Harvard Medical School.

Saurabh holds an M.D. and Ph.D. in Cancer Genetics from The Johns Hopkins School of Medicine, where he completed his graduate studies in Bert Vogelstein’s lab. He is an alumnus of Harvard Business School and Oxford University, studying General Management and Biophysics respectively. Saurabh received a B.Sc. in Biochemistry from the California Institute of Technology (Caltech).

Saurabh’s passion for advancing human health to bring novel medicines for patients has been the compass that has guided him in his educational and professional pursuits.

Tia Bush serves as Chief Quality Officer for Centessa Pharmaceuticals. Tia is a global leader who brings nearly thirty years of biotechnology quality experience to the company.

Tia’s extensive career has been spent in quality related roles of increasing responsibility at Amgen, where she joined in 1993. Most recently, Tia was Chief Quality Officer and Senior Vice President, Global Quality/Environment, Health, Safety and Sustainability where she was responsible for developing, maintaining, and continuously improving the quality management and EHSS management systems. She led an organization of more than 1,400 quality and safety professionals.

Tia currently sits on the Board of Directors for PDA and USC Health Services. She holds a B.A. in Biological Sciences with a minor in Chemistry from the University of Southern California, Los Angeles, USA.

David Chao, Ph.D., is Chief Administrative Officer of Centessa Pharmaceuticals. Most recently, Dave held the roles of President and Chief Executive Officer of Stowers Institute for Medical Research and President and Chief Executive Officer of BioMed Valley Discoveries.

Dave was also the President at The Graduate School of the Stowers Institute for Medical Research from 2010-2018 and a member of the Board of Directors for the American Century Companies from 2012-2020.

Earlier in his career, Dave was Head of Strategic Alliances Global Operations at the Novartis Institutes of BioMedical Research and a consultant in McKinsey & Company’s Pharmaceutical and Medical Product Practice.

Dave holds a Ph.D. in Biology from M.I.T. and a combined A.M. and A.B. in Biology from Harvard University.

Iqbal Hussain is General Counsel of Centessa Pharmaceuticals and is responsible for the leadership of our Legal, Compliance, IP and Corporate functions.

Prior to joining Centessa, Iqbal served as a Partner in the Global Corporate Group at Reed Smith, LLP where he led the life sciences transactional practice across EMEA from September 2019 to January 2021.

Before joining Reed Smith, Iqbal was Legal Director for Mergers & Acquisitions at Johnson & Johnson. From February 2014 to August 2019, he was Senior Counsel and a member of the leadership team at the Johnson & Johnson EMEA Innovation Centre in London.

Iqbal began his career at Slaughter and May where he advised clients on public and private mergers and acquisitions. Iqbal was a Senior Associate in the Corporate Mergers & Acquisitions team at Ropes & Gray, LLP.

Iqbal received an LLB from the University of Sheffield in 2004.

Thomas Templeman, Ph.D., serves as the Chief Technology Officer at Centessa Pharmaceuticals. Tom has over twenty-five years of experience in diagnostic and pharmaceutical manufacturing, biopharmaceutical process development, and implementation of quality systems.

Prior to joining Centessa, Tom was the Senior Vice President of Pharmaceutical Operations and Quality at Nuvation Bio. He previously served as Chief Operating Officer of Graybug Vision and Senior Vice President, Pharmaceutical Operations and Quality Assurance, at Axovant Sciences.

Earlier in his career, Tom served as Senior Vice President of Pharmaceutical Operations and Quality at Medivation, Vice President of Manufacturing Science and Technology at Hospira, Senior Vice President, Integrated Supply Chain at Liquidia Technologies, and in various leadership roles at Johnson & Johnson, where he worked for thirteen years in several capacities.

Tom earned a B.S. in Biology from the University of Santa Clara, a Ph.D. in Biological Sciences from Dartmouth College, and was a post-doctoral fellow at Harvard University. He also obtained six Sigma Black Belt Certifications while at Johnson & Johnson.

Marella Thorell has served as our Chief Accounting Officer since April 2021 and previously served as Head of Finance. Prior to that, Marella was the Chief Financial Officer of Palladio Biosciences, leading Palladio’s finance operations and capital strategy and execution.

Before joining Palladio, Marella served in various capacities at Realm Therapeutics (Nasdaq: RLM), including Chief Financial Officer, Chief Operating Officer and Executive Director. In this role, she led accounting and financial reporting operations and helped transition Realm’s focus to drug development following a strategic overhaul. She was also responsible for divesting domestic and international operating businesses and in-licensing and out-licensing assets.

Earlier in her career Marella worked for Campbell Soup Company (NYSE: CPB) in finance and operational roles of increasing responsibility and at Ernst & Young, LLP where she earned a C.P.A.

Marella serves on the Boards of Essa Pharm (Nasdaq: EPIX) and Vallon Pharmaceuticals (Nasdaq: VLON), where she chairs the Audit Committee. She also sits on the Board of Living Beyond Breast Cancer (lbbc.org).

Marella earned a B.S. in Business from Lehigh University, magna cum laude.

Gregory Weinhoff, M.D., M.B.A., is Chief Financial Officer of Centessa Pharmaceuticals. Most recently, Greg was a Co-Founder and Chief Financial and Chief Business Officer at Arvelle Therapeutics B.V. In that role, he was responsible for sourcing cenobamate, a novel anti-seizure medicine with best-in-class efficacy, negotiating the license with SK Biopharmaceuticals for European rights, and raising a $207.8M startup financing which was one of the largest startup financings for a European biopharma. Greg played a key role in preparing the Arvelle organization for commercialization and driving the strategic sale process which resulted in the $960M acquisition by Angelini Pharma.

Previously, Greg was Chief Financial Officer at Axovant Sciences, Inc. where he oversaw Finance, Accounting, Investor Relations and Business Development. At Axovant, he was the Principal Financial and Accounting Officer for SEC purposes and was responsible for three public financings, a private placement and a venture debt financing.

Before becoming Chief Financial Officer of Axovant, Greg spent fifteen years as an early-stage healthcare venture capitalist at CHL Medical Partners. He was the founding Chief Executive Officer and sole Series A investor in Amicus Therapeutics where he remained a Board member and member of the Audit Committee through its IPO in 2009. Prior to graduate school, Greg was a financial analyst in Morgan Stanley & Co.’s healthcare corporate finance group.

Greg holds an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School, and an A.B. in Economics from Harvard College.

Dr. Antoine Yver, M.D., M.Sc., serves as Chief Medical Officer at Centessa Pharmaceuticals. Antoine brings more than 30 years of global experience in the pharmaceutical industry to Centessa and has led the approvals of 11 different drugs, including Tagrisso®, Lynparza®, and Enhertu®. He led the development of Tagrisso® in 2 years 7 months from first human dose to U.S. approval and its rapid deployment to all other major regions, which was the fastest ever for an anti-cancer drug. Antoine joins Centessa from Daiichi Sankyo, where he served as Executive Vice President and Global Head, R&D Oncology, and Chair of the Cancer Enterprise.

Previously, Antoine was with AstraZeneca, most recently serving as Senior Vice President, Global Medicine Head, Oncology, and Global Medicines Development China Lead.

Earlier, Antoine held various clinical development roles at Schering-Plough/Merck, Johnson & Johnson, Aventis Pharmaceuticals, Inc., Rhône-Poulenc Rorer, Inc, Applied Immune Sciences, Inc, and Chugai-RP.

Antoine is a Pediatric Oncologist and holds an M.D. from Université Paris-Saclay.

Board of Directors.

Francesco De Rubertis, Ph.D., is Chairman of the Board at Centessa Pharmaceuticals and a Co-Founder and Partner at Medicxi. Prior to Medicxi, Francesco was a Partner at Index Ventures for nineteen years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and adopted.

Francesco’s prior investments include CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ: NERV), Molecular Partners (Swiss: MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix), Profibrix (acquired by The Medicines Company), and Versartis (NASDAQ: VSAR).

Francesco received a B.A. in Genetics and Microbiology from the University of Pavia in Italy and a Ph.D. in Molecular Biology from the University of Geneva in Switzerland after which he became a postdoctoral scientist at the Whitehead Institute at M.I.T. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva.

In November 2017, Francesco was named in the first "Bloomberg 50” as one of the Top 50 entrepreneurs and innovators who helped to define Global Business in 2017.

Francesco also serves on the boards of Rivus Pharmaceuticals and Inexia.

Robert M. Califf, M.D., MACC, is an internationally recognized expert in the development of medicines and quality healthcare delivery with more than forty years of clinical research and health outcomes expertise.

Robert currently works as the Head of Strategy and Clinical Policy for Verily and Google Health.

Robert served as the 22nd Commissioner of Food and Drugs for the United States Food and Drug Administration from 2016 to 2017 and has directed major initiatives targeted at improving methods and infrastructure for clinical research.

As a graduate of the Duke University School of Medicine, he became the Vice Chancellor for Health Data Science for the Duke University School of Medicine. He is the founding director of the Duke Clinical Research Institute and remains a board-certified Cardiologist.

Arjun Goyal, M.D., M.Phil., M.B.A., is a Co-Founder and Managing Director of Vida Ventures. Arjun focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Arjun serves as a Director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Pionyr Immunotherapeutics and has been involved in Vida Venture’s investments in Homology Medicines (NASDAQ: FIXX), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios Bio (acquired by Bayer). Before co-founding Vida Ventures, Arjun was a life sciences investor at 5AM Ventures.

Arjun received his B.S. in Medical Science, Diploma in French, and his M.D. degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in Internal Medicine in Sydney. He received his M.Phil. in Bioscience Enterprise from the University of Cambridge and his M.B.A. from Harvard Business School. Arjun has received multiple awards for his work, including the American Australian Association Education Fellowship, Robert Kaplan HBS Life Science Fellowship, Oxford Clarendon Scholarship, Commonwealth Scholarship, and Gates Cambridge Scholarship.

He is a co-inventor on one patent and had served on the editorial board of an international scientific journal. He serves on the Committee for the American Australian Association Education Fellowship.

Mary Lynne Hedley, Ph.D., is a senior fellow and strategic advisor at The Broad Institute of M.I.T. and Harvard and Co-Founder, former President, Director and Chief Operating Officer at TESARO, Inc.

Mary Lynne has extensive experience in the discovery and development of new medicines, formerly serving as Executive Vice President and Chief Scientific Officer at MGI PHARMA, Executive Vice President of Eisai Corporation of North America, Executive Vice President of Operations, and Chief Scientific Officer of Abraxis BioScience.

Mary Lynne also sits on the Veeva Systems (NASDAQ: VEEV) Board of Directors and is a member of the Helsinn Holdings’ Board of Directors.

Mary Lynne holds a Ph.D. in Immunology from the University of Texas Southwestern Medical Center and a B.S. in Microbiology from Purdue University. In addition, she completed two consecutive postdoctoral fellowships at Harvard University.

Aaron Kantoff is a Venture Partner on the Medicxi investment team. Prior to joining Medicxi, Aaron was a partner with Apple Tree Partners (ATP), where he was a key member of the life science investment team since 2011. While at ATP, he played a leading role in assembling several ATP portfolio companies, previously serving on the boards of Akero Therapeutics (NASDAQ: AKRO), Corvidia Therapeutics (acquired by Novo Nordisk), Elstar Therapeutics, Limelight Bio, and Syntimmune (acquired by Alexion). During his time at ATP, Aaron was also a Board Observer at Stoke Therapeutics (NASDAQ: STOK) and led many of ATP's crossover and public biotech investments.

Prior to joining ATP, Aaron held roles in private equity and investment banking.

Aaron received a B.S. in Finance and International Business from NYU Stern's School of Business.

Aaron also serves on the boards of RayzeBio and Silagene and two private biotech companies for which he was a founding board member.

Samarth Kulkarni, Ph.D., has served as CRISPR Therapeutics’ Chief Executive Officer since 2017. He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer and was appointed to President and Chief Business Officer before becoming Chief Executive Officer.

Prior to joining CRISPR Therapeutics, Sam was a Partner at McKinsey & Company, where he had a leading role in the pharmaceutical and medical products practice. While at McKinsey, he co-led the biotech practice, where he focused on strategy and operations, and led initiatives in areas such as personalized medicine and immunotherapy.

Sam also serves on the Board of two precision oncology companies, Black Diamond Therapeutics and Repare Therapeutics and on the board of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO). Previously, Sam served as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR Therapeutics and Bayer.

Sam received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research on the delivery of biological drugs and in the field of molecular diagnostics.

Sam has authored several publications in leading scientific and business journals.

Saurabh Saha, M.D., Ph.D., is Chief Executive Officer and a member of the Board of Directors of Centessa Pharmaceuticals. Most recently, as Senior Vice President of Research & Development at Bristol Myers Squibb, Saurabh led translational medicine across all therapeutic areas spanning discovery, early development through late development, and commercialization. In 2019, he led the Research & Development diligence in the acquisition of Celgene by BMS and subsequently managed key aspects of the integration across both organizations. During his tenure, Saurabh laid the foundation for the BMS Research & Development headquarters in Cambridge, MA, serving as site head and establishing a research focus on discovering new cancer treatments for immunotherapy resistance.

Previously, Saurabh was a Venture Partner at Atlas Venture where he held leadership positions with a number of its portfolio biotech companies, including Chief Medical Officer of Synlogic, and Chief Executive Officer of Delinia until its sale to Celgene in early 2017. In 2008, he established the translational research and development organization at BioMed Valley Discoveries where he served as Chief Scientific Officer and later President and was responsible for leading the development and demonstrating human effectiveness of two first-in-class cancer therapies. Earlier in his career, Saurabh was a Management Consultant in the pharmaceutical practice at McKinsey & Company and subsequently appointed Director and Head of the New Indications Discovery Unit at Novartis. He is on the editorial boards of a number of medical journals and is an Associate member and Global Clinical scholar at Harvard Medical School.

Saurabh holds an M.D. and Ph.D. in Cancer Genetics from The Johns Hopkins School of Medicine, where he completed his graduate studies in Bert Vogelstein’s lab. He is an alumnus of Harvard Business School and Oxford University, studying General Management and Biophysics respectively. Saurabh received a B.Sc. in Biochemistry from the California Institute of Technology (Caltech).

Saurabh’s passion for advancing human health to bring novel medicines for patients has been the compass that has guided him in his educational and professional pursuits.

Carol Stuckley, M.B.A. is a global, strategic financial executive with proven success leading finance teams and creating shareholder value for healthcare companies.

Carol was formerly Chief Financial Officer and Senior Vice President HPS for TransUnion, Inc. Previously, Carol was a consultant at Harris & Dickey and RES Partners, and served as Chief Financial Officer, Vice President, Finance at Galderma (Nestlé Skin Health S.A.).

Carol held a nearly 23 year tenure in financial roles of increasing responsibility at Pfizer, including most recently as Assistant Treasurer, Vice President, Finance and Corporate Officer of Pfizer.

She currently sits on the Ipsen Board of Directors and serves as Chairperson of the Audit Committee.

Carol holds a Master of Arts in Economics and an MBA in International Finance from the Temple University’s Fox Business School.

Brett Zbar, M.D., serves as Managing Director and Global Head of Life Sciences at General Atlantic, a leading global growth equity firm providing capital and strategic support for growth companies.

Before joining General Atlantic in 2020, Brett was a Managing Director at Foresite Capital, where he focused on backing leading healthcare entrepreneurs and companies at all stages. While at Foresite, Brett served as a board member or observer at multiple companies, including ConnectiveRx, Kinnate Biopharma, ORIC Pharmaceuticals (OTCMKTS: OCLDY), Peloton Therapeutics (acquired by Merck & Co.), Pharvaris, Replimune (NASDAQ: REPL), Signant Health, Turning Point Therapeutics (NASDAQ: TPTX) and VenatoRx Pharmaceuticals.

Prior to that, Brett was a Partner at Aisling Capital, where he invested in life sciences companies developing and commercializing innovative products, services and technologies.

Brett began his career in McKinsey & Company's Pharmaceuticals and Medical Products practice and completed his internship in internal medicine on the Osler Medical Service at Johns Hopkins Hospital. He received his M.D. from Harvard Medical School and holds a B.A. in English and Molecular Biophysics and Biochemistry from Yale University.

Investors.

investors-logo-medicxi
investors-logo-general
investors-logo-vida
investors-logo-janus

U.S.-based, healthcare focused fund

investors-logo-boxer
investors-logo-cormorant
investors-logo-rower
investors-logo-venrock
investors-logo-wellington
investors-logo-bvf
investors-logo-ecor1
investors-logo-franklin
investors-logo-capital
investors-logo-samsara
investors-logo-lifesci